FEMASYS INC
FEMYNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $1.6M | $1.1M | $1.2M | $1.2M | $1.0M |
| Operating income | −$17.6M | −$17.8M | −$14.5M | −$11.6M | −$8.3M | −$6.9M |
| Net income | −$18.6M | −$18.8M | −$14.2M | −$11.4M | −$7.5M | −$6.9M |
| Total assets | $20.7M | $12.4M | $27.8M | $16.9M | $28.6M | $7.6M |
| Total liabilities | $14.9M | $10.1M | $9.4M | $1.7M | $2.2M | $4.1M |
| Equity | $5.9M | $2.3M | $18.4M | $15.2M | $26.3M | −$51.8M |
| EPS (diluted) | $-0.47 | $-0.85 | $-0.93 | $-0.96 | $-1.12 | $-7.20 |
| Shares out. | 27.1M | 22.1M | 11.9M | 11.8M | 9 | 993,124 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −767.0%
- Net margin
- −812.3%
- Return on equity
- −317.4%
- Return on assets
- −89.9%
- Return on capital (ROCE)
- −102.9%
- Liabilities / assets
- 71.7%
- Debt / equity
- 2.53×
- Book value / share
- $0.22
- Revenue growth (YoY)
- 40.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -24.17distress
- Accruals / assets
- 0.3%clean
- Beneish M-Score
- -2.27normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Pharmacyte Biotech, Inc.Passive (13G)Mar 18, 2026
- Dauntless Investment Group, LlcPassive (13G)Nov 14, 2025
- Alumni Capital LpPassive (13G)Sep 4, 2025
- Chernett JoreyPassive (13G)Aug 5, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.0M | 4.3 | +1.2% |
| Apr 30, 2026 | 1.9M | 5.4 | -0.0% |
| Apr 15, 2026 | 1.9M | 5.0 | -5.0% |
| Mar 31, 2026 | 2.0M | 2.6 | +2.4% |
| Mar 13, 2026 | 2.0M | 3.8 | +2.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 13, 2026
- Results of operationsMay 8, 2026
- Shareholder voteApr 29, 2026
- Director / officer change · Other material eventApr 1, 2026
- Results of operationsMar 31, 2026
- Entered a material agreement · Unregistered equity sale · Director / officer changeMar 20, 2026
- Delisting / listing-standard noticeJan 15, 2026
- Other material eventDec 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.